• CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from Needham & Company LLC

    来源: Buzz FX / 13 2月 2025 06:21:11   America/Chicago


    CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from Needham & Company LLC Written by MarketBeat February 13, 2025 Share Link copied to clipboard. Needham & Company LLC reaffirmed their buy rating on shares of CRISPR Therapeutics ( NAS
    Read more...
分享